{"filings":[{"id":101294,"accession_number":"0001654954-26-002928","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Zivo Bioscience to voluntarily deregister, cease SEC reporting; CFO and director resign","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO William Sullivan resigns effective March 30, 2026; board member Alison Cornell resigns immediately as part of cost-cutting measures.","Company expects to file Form 15 on March 30, 2026 to suspend SEC reporting obligations and delist from OTC markets.","CEO letter states anticipated revenue from AgTech distribution partner in coming months, targeting first-time positive cash flow.","Board compensation eliminated; CEO continues to invest personal capital; alignment with shareholders emphasized.","University of Georgia granted funds to study Zivo's product for Avian Influenza using company's algal immune-modulating technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117654,"accession_number":"0001654954-25-014296","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Keith Marchiando resigns; William Sullivan appointed Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Marchiando resigns as CFO effective Dec 31, 2025; receives $27,040/mo through Dec 31, 2026.","Marchiando retains option for 150,000 shares at $7.96, exercisable until June 30, 2027; all other options cancelled.","William A. Sullivan appointed Interim CFO effective Dec 19, 2025 as independent contractor at $285/hour.","Sullivan's contract is initially 60 days, auto-renewing monthly; no other compensation or equity.","Marchiando's separation includes confidentiality and non-disparagement obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134090,"accession_number":"0001654954-25-010579","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ZIVO CEO letter highlights algae antioxidant validation and animal health progress","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Independent analysis showed ZIVO's algae has nearly double SOD activity vs. a competing algae product.","Poultry avian influenza study: treated birds showed delayed transmission, lower viral shedding, faster immune response.","Management and board personally invested in the Company, signaling conviction in undervalued stock.","Company targets $4.5B antibiotic-free feed market growing at 8.2% CAGR through 2033.","CEO acknowledges liquidity challenges but expects near-term revenue from nutraceutical commitments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134089,"accession_number":"0001654954-25-009772","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Nola Masterson resigns from Zivo Bioscience board effective August 12, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ms. Masterson resigned immediately; no disagreement with company operations, policies, or practices.","She was chair of the Nominating and Governance committee and member of Audit and Compensation.","Board has not yet named a replacement for the open seat.","Company expressed gratitude for her service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134088,"accession_number":"0001654954-25-008035","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zivo Bioscience raises $250k initial tranche in $2M convertible debt offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $250k bridge promissory note with 10% annual interest, compounded annually; due after 2 years or upon $5M+ equity financing.","Note converts at lower of issuance price or 80% of qualified financing share price; prepayment allowed at 115% of principal.","Accompanying warrant to purchase 1,793 shares at issuance closing price, 5-year term, immediately exercisable.","Total offering up to $2M; proceeds for general operations; notes unsecured and junior to secured debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150838,"accession_number":"0001654954-25-006837","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zivo Bioscience shareholders elect directors, ratify auditor, and approve executive compensation at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected John B. Payne and Alison A. Cornell as Class III directors with 1,681,190 and 1,681,001 votes for, respectively; broker non-votes 792,911.","Ratified BDO USA, P.C. as independent auditor for fiscal year 2025 with 2,438,089 votes for, 53,549 against, 15,420 abstain.","Advisory approval of named executive officer compensation: 1,665,583 for, 48,443 against, 121 abstain; broker non-votes 792,911.","Total shares present at meeting: 2,507,058 (66.11% of outstanding common stock)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169775,"accession_number":"0001654954-25-000805","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Zivo Bioscience issues 191,698 shares, raises ~$1.5M from accredited investor since Nov 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 75,000 shares at $20.19 each to one accredited investor, gross proceeds ~$1.5M.","Granted 38,478 restricted shares to non-employee directors under 2024 Equity Incentive Plan.","Issued 78,320 shares to investors under Exchange Program in exchange for cancellation of co-development agreements.","Total shares outstanding as of Jan 20, 2025: 3,738,033.","Shares issued in unregistered transactions exempt under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169774,"accession_number":"0001654954-25-000453","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Zivo Bioscience swaps revenue share obligations for 212,260 shares; director affiliates participate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company authorized exchange of up to 212,260 shares for cancellation of Participation Agreements with accredited investors.","To date, completed exchanges with two investors for 14,200 shares of common stock.","Director Laith Yaldoo manages two entities expected to participate in the Exchange Program.","Exchange eliminates investor rights to future revenue share cash and a $5.3M buy-out option.","Investors retain Warrants issued under the original Participation Agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169773,"accession_number":"0001654954-25-000173","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ZIVO BIOSCIENCE moves principal executive office to Troy, Michigan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective January 6, 2025, principal executive office changed to 2125 Butterfield Drive, Suite 100, Troy, MI 48084.","Previous address was 21 East Long Lake Road, Suite 100, Bloomfield Hills, MI 48304.","Company telephone number (+1 248 452-9866) remains unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186824,"accession_number":"0001654954-24-014503","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Zivo restructures $277k debt into unsecured notes payable over 24 months at 1%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Debt Settlement Agreements with three creditors executed on Nov 12, 2024.","Total principal $277,254 via notes to Howard Shapiro ($185.5k), Merger Masters ($40.3k), Financial Trading ($51.4k).","Notes bear 1% annual interest, payable in 24 equal monthly installments starting Nov 30, 2024.","Prepayment permitted without penalty; customary events of default apply.","Restructuring converts existing obligations into unsecured promissory notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186823,"accession_number":"0001654954-24-013107","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Zivo Bioscience sells 169,022 unregistered shares at avg $10.44 to accredited investors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 169,022 shares between Aug 22 and Oct 17, 2024, at $8.34 to $16.31 per share (avg $10.44).","Of total, 52,802 shares sold to related parties at avg $9.68 per share.","No solicitation or underwriting discounts; exempt under Section 4(a)(2) and Regulation D.","As of Oct 17, 2024, outstanding shares total 3,535,134 (dilution ~4.8% from offering).","Proceeds used for general corporate purposes (not stated, typical for such offerings)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203361,"accession_number":"0001654954-24-009069","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ZIVO Bioscience appoints Laith Yaldoo to board, expands to 5 members","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 4 to 5 members; Laith Yaldoo appointed effective July 11, 2024.","Yaldoo is managing member of HEP Investments LLC; background in biotech, healthcare, and card processing.","He will stand for election as a Class I director at the 2026 annual meeting.","No family relationships or related party transactions with current officers/directors.","Yaldoo will participate in the Company’s standard outside director compensation program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219742,"accession_number":"0001654954-24-007730","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Zivo shareholders elect Masterson as director, ratify BDO, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Nola E. Masterson elected Class II director (1,155,796 for, 80,935 withheld; 625,589 broker non-votes).","BDO USA, LLP ratified as auditor for FY 2024 (1,767,252 for, 94,680 against, 388 abstain).","Advisory say-on-pay approved (1,191,591 for, 44,773 against, 367 abstain; 625,589 broker non-votes).","Total shares voted: 1,862,320 (66.4% of outstanding common stock)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219740,"accession_number":"0001654954-24-007479","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K/A","filed_at":"2024-06-07T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Zivo Bioscience amends 8-K to correct date typo in director stock award from 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrects date in Item 1.01 from erroneous date to December 29, 2023.","Board approved 261,619 shares to three non-employee directors for unpaid 2023 fees of $172,670.","Shares issued at $1.20 per share (Dec 29, 2023 close), grossed up for taxes at 45%.","Directors Cornell (95k), Masterson (85k), Maggiore (82k) accepted grants on June 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219741,"accession_number":"0001654954-24-007455","cik":1101026,"company_name":"Zivo Bioscience, Inc.","ticker":"ZIVO","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["1.01","5.02","3.02","9.01"],"status":"ready","headline":"Zivo Bioscience adopts new Director Equity Plan, boosts share reserves, grants equity to directors and officers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Adopted 2024 Director Equity Plan (875k shares, auto-increase 5%/yr). Director cash fee raised from $40k to $50k, eligible for restricted stock/RSUs.","Amended 2021 Plan reserve from 166,666 to 1,000,000 shares; terminated 2019 Plan.","Granted 127,364 restricted shares to directors replacing cancelled options; additional 261,619 shares for unpaid 2023 fees.","Issued 1,031,425 stock options to officers: CEO John Payne (217,431), CFO Keith Marchiando (444,498) replacing prior options and cash bonus.","Total unregistered securities issued: 426,671 common shares and options for 1,031,425 shares; outstanding shares at 3,278,807."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16860000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}